Development Milestone Event Development Milestone Payment Sample Clauses
The Development Milestone Event Development Milestone Payment clause defines the conditions under which payments are made to a party upon the achievement of specific project milestones. Typically, this clause outlines a schedule of key deliverables or events—such as completion of a prototype, regulatory approval, or final product delivery—each triggering a corresponding payment. By linking payments to tangible progress, this clause ensures that compensation is tied to performance, incentivizing timely completion and reducing financial risk for the paying party.
Development Milestone Event Development Milestone Payment. [***] [***]
Development Milestone Event Development Milestone Payment. (in Dollars)
Development Milestone Event Development Milestone Payment. First Regulatory Approval in the United States of an SMA Licensed Product $ [***] (ii) First occurrence of both (a) Regulatory Approval by the $ [***] CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EMA or an MMC in the EU of an SMA Licensed Product and (b) Reimbursement Approval by an MMC in the EU of such SMA Licensed Product
Development Milestone Event Development Milestone Payment. Commencement of a Phase I Clinical Study for a Licensed Product or a Buck Licensed Product $[***]
Development Milestone Event Development Milestone Payment. For Each Metsera GLP-1 Platform Licensed Product or Metsera Amylin Platform Licensed Product (b) For Each of (i) First DD02S Licensed Product, (ii) First DD03 Licensed Product, (iii) First D&D GLP-1 Platform Licensed Product, and (iv) First D&D Amylin Platform Licensed Product (c) For Each Subsequent (i) DD02S Licensed Product, (ii) DD03 Licensed Product, (iii) D&D GLP-1 Platform Licensed Product, and (iv) D&D Amylin Platform Licensed Product 1. [***] [***] [***] [***]
Development Milestone Event Development Milestone Payment. [*] $[*], in the form of cash or in the form of unregistered common stock of Licensee (valued using a 30-day VWAP of Licensee’s common stock traded on Nasdaq beginning on the date the milestone is publicly announced). For the avoidance of doubt, Licensor will have 10 days to elect whether to accept the payment in cash or stock. Notwithstanding the foregoing, if Licensee undergoes a Change in Control, any payment owed pursuant to this Development Milestone Event will be made in cash and not in stock.
Development Milestone Event Development Milestone Payment. First patient dosed in the first Phase II Clinical Trial of a Product in the GSK Territory $30,000,000 First patient dosed in the first Phase III Clinical Trial of a Product in the GSK Territory $100,000,000 [***] [***] [***] [***] Each Development Milestone Payment shall be paid only one time, regardless of the number of Products that achieve the corresponding Development Milestone Event or the number of times a given Product achieves such corresponding Development Milestone Event (including for additional Indications). GSK shall notify Arrowhead within [***] Business Days following the achievement of a given Development Milestone Event by GSK or any of its Affiliates (or, in the event that a Development Milestone Event is achieved by or on behalf of a Sublicensees, within [***] Business Days following GSK’s receipt of notice from such Sublicensee with respect to the achievement of such Development Milestone Event, as applicable), and the corresponding Development Milestone Payment shall be due within [***] days following GSK’s receipt of a Valid Invoice in accordance with Section 5.6 for such Development Milestone Payment. In the event that GSK (or its Affiliate or Sublicensee) achieves any subsequent Development Milestone Event under this Section 5.2 without a prior Development Milestone Event having been first achieved, then the Development Milestone Payment for such skipped Development Milestone Event shall be paid at the same time as the Development Milestone Payment for the subsequent Development Milestone Event, except in the case of any skipped Development Milestone Event that is specific to a jurisdiction, where the subsequent milestone event is achieved with respect to a different specific jurisdiction.
Development Milestone Event Development Milestone Payment. [***] [ ***] [***] [ ***] [***] [ ***] [***] [ ***] [***] [ ***] [***] [ ***] [***] [ ***] [***] [ ***] [***] [ ***] [***] [ ***]
Development Milestone Event Development Milestone Payment. Commencement of a Phase I Clinical Study for a Royalty Product $[***]
Development Milestone Event Development Milestone Payment. [**] ● $[**] Dollars) for [**] Target or its Replacement Collaboration Target ● $[**] Dollars) for [**] Target or its Replacement Collaboration Target ● $[**] Dollars) for an [**] or its Replacement Collaboration Target